IXO Therapeutics
IXO is a biotechnology company researching and developing novel immunotherapeutics targeting the innate immune system.
Focusing on the initiators of the adaptive immune response, IXO's products address significant unmet clinical need in areas of high commercial value. Based in the UK, IXO's products are in late-stage research and preclinical development based on IP derived from both NERC
and the University of Oxford.
Press Release: Isis Participates in new Start-up Company Developing Novel Medicines